ANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments.
Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are pleased to report progress on our upcoming first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.”
“Last month, we announced that we have begun the recruiting and enrollment process for the clinical trial. This was a major milestone as it marks the next phase of development for BICX104. The BICX104 clinical study is a Phase 1, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection. We are in the recruiting phase and look forward to providing progress updates as they become available.”
“Additionally, we saw an increase in revenue in the first quarter of 2022 due to the increased number of patients treated at licensed clinics. Furthermore, we were pleased to see that membership/program fees also increased for the first quarter of 2022 due to more customers signing up for our UnCraveRx™ Weight Loss Management Program.
At the same time, we continue to carefully manage expenses and reduced operating expenses by nearly 30%.”
BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002,
“Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional).” The Company has an active Investigational New Drug (IND) status, and the FDA has deemed the 505(b)(2) abbreviated pathway acceptable, as well the opportunity to seek eventual dual indication on the product for OUD and Alcohol Use Disorder (AUD).
A copy of the Company’s annual report on Form 10-Q for the first quarter ended March 31, 2022 has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC 212- 671-1020 x304 bicx@crescendo-ir.com
Media Contact PhillComm Global BioCorRx@PhillComm.Global 704-942-1557
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Shoppers returned to the malls of Beijing on Sunday as the Chinese capital relaxed pandemic restrictions after declaring a small but persistent COVID-19 outbreak effectively under control. A partial reopening of stores and offices in Beijing was welcomed by a weary populace and struggling shopkeepers eager for life to return to normal. Coupled with a gradual easing of restrictions in Shanghai, it signaled that the worst is over in the twin outbreaks in China's most prominent cities.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
For a decade, Florida lawmakers have refused to expand eligibility for the public health insurance program, Medicaid, to all low-income adults as prescribed under the Affordable Care Act.
Alzheimer's disease impacts women disproportionately, as both patients and caregivers. Of the 6.5 million Americans currently diagnosed with the disease, almost two-thirds of them are women – a sobering 4.3 million women. Scientists and doctors still do not fully understand why this disease, which is the most common type of dementia, is especially bad for women. Some of this disparity may be explained by women's longer lifespan than men, losing estrogen at menopause, greater brain effects of con
The accelerator program uses Target’s scale to help under resourced founders with access, education and resources.
Michelle Fishman calls it the “worst-case scenario that you don’t really think through.” After a three-week vacation in Greece, the 52-year-old hotel art consultant from Miami and her husband took pre-departure coronavirus tests required to fly home from overseas. She tested positive, he did not. Although coronavirus travel restrictions have eased across many parts of the world, the United States still requires all international air passengers to present a negative test taken within one day of d
At this point in the pandemic, it's fairly likely you've had COVID at least once, as the Centers for Disease Control and Prevention (CDC) has estimated that there have been more than 83 million coronavirus infections in the U.S. alone, which translates to around 60 percent of all Americans. Our country has also reached the tragic milestone of one million COVID deaths, while infections and hospitalizations are rising once again. Since the end of 2020, however, virus experts have continued to push
Each week, we offer you a roundup of noteworthy coronavirus coverage.
To the public, the monkeypox outbreak has echoes of the early days of the COVID-19 pandemic. But scientists say it's not the same at all.
For instance, small-cap companies -- that is, those with market caps between $300 million and $2 billion -- tend to carry above-average risk. Let's look at two small-cap companies that could double your money within the next couple of years and deliver solid returns in the long run if they can navigate the road ahead: BioXcel Therapeutics (NASDAQ: BTAI) and Planet 13 Holdings (OTC: PLNH.F). The biotech currently boasts a market capitalization of $379 million and a share price of $11.75.
The cases, which have so far puzzled health officials, have been reported in 33 different countries since early April.
The pharma giant's drug combo is now just months away from potential U.S. approval for a type of liver cancer.
A Brooklyn judge sprang a violent mobster from prison because he said the federal Bureau of Prisons did a lousy job taking care of the wiseguy’s medical problems. Federal Court Judge Raymond Dearie issued a scathing ruling Thursday, saying the feds weren’t competently treating made man Vincent “Chickie” DeMartino’s maladies. The goodfella had more than two years left of his 25-year sentence ...
An investment climate that's suddenly turned chilly may leave promising companies out in the cold.
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
Jeff Bridges' battle with COVID-19 while going through chemotherapy for lymphoma left him "pretty close to dying," the actor has revealed.